Jean-Sébastien Annicotte
  • E-mail :[email]
  • Phone : 0320974254
  • Location : Lille, France
Last update 2022-09-06 13:07:46.663

Jean-Sébastien Annicotte PhD in molecular and cellular biology

Course and current status

ANNICOTTE Jean-Sébastien, Born December 15, 1975 



2022- Group leader of the "Molecular and cellular pathophysiology of metabolic diseases" team 6 at French National Institute of Health and Medical Research (INSERM) UMR1167 - RID-AGE, Lille University, Institut Pasteur de Lille, Lille, France

2022-2025 FRM team, INSERM UMR1167 - RID-AGE, Lille University, Institut Pasteur de Lille, Lille, France           

2005 – INSERM Researcher, Chargé de Recherche (Tenure), France          


2007-  Habilitation à Diriger les Recherches (HDR), Montpellier University, France (Academic degree required for being accredited as head of research in France)

2000-2004     PhD in Molecular and Cellular Biology, University Louis Pasteur, IGBMC, Strasbourg, France - PhD Supervisor: Pr. Johan Auwerx 

1999 MSc Biology and Health, Lille 1 University, Lille, France 

1996-1999 BSc Biochemistry, Lille 1 University, Lille, France 


2012- 2022 Group leader INSERM UMR1283 -EGID, Lille University, Institut Pasteur de Lille, Lille, France

2011 – 2012 INSERM Researcher, Chargé de Recherche, Institute of Molecular Genetics of Montpellier, CNRS UMR5535, Montpellier, France; Director: Dr M. Piechaczyk

2005 – 2011 INSERM Researcher, Chargé de Recherche, Institute of Research Cancer of Montpellier, INSERM U896, Montpellier, France; Director: Dr A. Pélegrin

2004 – 2005 Postdoctoral Research Associate, Avenir Team "Metabolism & Cancer", INSERM U540, Montpellier, France; Team leader: Dr L. Fajas, Director: Drs F. Vignon and J.C. Nicolas 

2000 – 2004 PhD in Molecular and cellular biology, IGBMC, Strasbourg, France; Director: Pr. Pierre Chambon, Team leader: Pr. Johan Auwerx


2022-2023 Research Grant from the French Society for Diabetes (PI)

2022-2025 Laureate of the FRM team award (PI)

2022-2024 Laureate of the Société francophone du Diabète Award (PI)

2020-2023 Laureate of the Marie Skłodowska-Curie COFUND Programme for Early-stage researchers in Lille (PhD program, PEARL, PI)

2020-2021 Industrial Chair from the Lille European Metropole and the I-SITE ULNE (PI)

2020-2022 Research Grant CPER-CTRL from the Institut Pasteur de Lille (PI)

2019-2021 Research Grant “StartAIRR” from the Hauts-de-France Council/I-SITE ULNE (PI)

2018-2022 Research Grant “Sustain” from the I-SITE ULNE (PI)

2018-2020 Research Grant from the French Society for Diabetes (PI)

2018 Research Fellowship to Support Patenting Process (SATT Nord, PI)

2018-2021 Research Grant from the French National Agency (ANR PRC, PI)

2017 Research Fellowship to Support Patenting Process (SATT Nord, PI)

2016-2017 Research Grant from the European Foundation for the Study of Diabetes (PI)

2012-2015 Research Grant from Diabetes Research Association (PI)

2010 Excellence Research Award (INSERM)

2007 French National Diabetes Research Program, INSERM (PI) 

2005 INSERM Chargé de Recherche 2ndclass (ranked 1st)

2005 Young Researcher fellowship from INSERM

2005 Diabetes AREDIC Award


Evaluation committee

2018- 2021    Elected member of the Research Council of the University of Lille

2019- 2021    Vice-President of the ANR evaluation panel Physiology/Physiopathology 


2016-             Graduate Student Advisor, University of Lausanne, Switzerland

2014-             Jury Member of the PhD Program Selection, Lille, France 

2006-             PhD Thesis and HDR Reviewer and Jury Member (7 HDR & 17 PhD defense)

Grant peer reviewer for:

                        Agence Nationale de la Recherche (ANR, France), ANSES, Research Executive Agency of the European Council, Harvard Medical School (BADERC Grant)

Journal peer reviewer for:

                        Cell Reports, Diabetes, Diabetes Care, Diabetologia, EMBO Molecular Medicine, Plos Biology, Gut, Journal of Cellular Biology, Nat Comm…


                        French Society for Diabetes, European Association for the Study of Diabetes, French Purine Club 

Scientific summary

Metabolic homeostasis is controlled by fine-tuned and non-permanent modulations of gene expression, in response to extra-cellular stimuli, through post-translational modifications such as histone methylation or acetylation. This allows the cells to adapt to their environment to maintain cell integrity in response to metabolic challenges. 

Type 2 Diabetes (T2D) is characterized by high blood glucose levels and develops due to inadequate pancreatic β-cell function (i.e.insulin secretion) in the face of peripheral insulin resistance (i.eadiposetissue, muscle, liver). β-cell dysfunction is thought to have a major role in the pathogenesis of T2D. The restoration of β-cell mass and function has therefore become a field of intensive research seeking for the next generation of anti-diabetic drugs.

Tremendous efforts and illuminating investigations focus on deciphering epigenetic regulations–the subtle and reversible chemical modifications on DNA or proteins– that control metabolic tissue function. For several years, the team led by Dr Jean-Sebastien Annicotte has dissected the molecular links between insulin producing cells, insulin target tissues and T2D/obesity development. Especially, the team research has been focused on the role of cell cycle regulators and their transcriptional co-regulators in the control of metabolic homeostasis, T2D and obesity. 

Our research program aims to go beyond the current state-of-the-art by decoding the role of transcription factors and transcriptional co-regulators in metabolic homeostasis and adaptation. We develop an innovative framework to uncover the physiological and pathophysiological roles of these factors in the regulation of cellular responses during diabetes and obesity development. Our hypotheses are tested combining unbiased next-generation sequencing technology, mouse models, Cripsr/Casand human tissue samples to dissect the regulated processes involved in the control of metabolic homeostasis. Thereby, we hope to identify novel targets, open new research fields and emerging concepts for the prevention and treatment of T2D. 

Early scientific achievements

  • Generated a mouse model for the conditional inactivation of the orphan nuclear receptor Lrh-1using the Cre/LoxP technology
  • Designed molecular biology tools and established protocols to study LRH-1 cellular functions 
  • Elucidated key regulatory pathways controlled by LRH-1 in cellular models and in vivo
  • Implemented metabolic phenotyping experiments to study energy homeostasis in mice
  • Established pancreatic islet isolation protocols and b-cell physiology experiments 
  • Discovered the transcription factor E2F1 as a key regulator of pancreatic b-cell proliferation and function
  • Developed mouse models for the conditional inactivation and over-expression of the E2f1gene using the Cre/LoxP technology
  • Elucidation of the molecular mechanism of E2F1 and other cell cycle regulators in the control of muscle, liver and adipose tissue functions, in physiology and disease (T2D, obesity, Duchenne Muscular Dystrophy)
  • Developed high-throughput approaches for a better understanding of b-cell physiology (ChIP-seq, RNA-seq) and established Seahorse XFe24 and Pamgene technologies (for mitochondria and kinome analysis, respectively) 
  • Implemented lineage-tracing experiments using the Lox-STOP-Lox-TOMATO mouse model
  • Provided evidence of the epigenetic role of KAT2B in the control of insulin secretion and b-cell function during metabolic stress
  • Demonstrated the crucial role of the Cdkn2atumor-suppressor gene in adipose tissue browning process
  • Designed new targeted strategies for treating T2D with insulin-secretion stimulating small molecules (on-going patent)


Research Record 

Scientific production: 64 publications (50 original articles and 14 review articles), 1 patent pending and 3 invention disclosures

Sum of times cited without self-citations (according to ISI Web of Science, August 2022): 3161

h-index: 29

Image d’exemple